1. Home
  2. FCEL vs LBRX Comparison

FCEL vs LBRX Comparison

Compare FCEL & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FuelCell Energy Inc.

FCEL

FuelCell Energy Inc.

HOLD

Current Price

$13.57

Market Cap

592.3M

Sector

Energy

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

HOLD

Current Price

$32.76

Market Cap

602.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCEL
LBRX
Founded
1969
2015
Country
United States
United States
Employees
629
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
592.3M
602.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FCEL
LBRX
Price
$13.57
$32.76
Analyst Decision
Hold
Strong Buy
Analyst Count
4
5
Target Price
$8.31
$46.60
AVG Volume (30 Days)
5.8M
267.8K
Earning Date
06-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.77
N/A
Revenue Next Year
$42.46
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.66
$13.40
52 Week High
$14.30
$33.47

Technical Indicators

Market Signals
Indicator
FCEL
LBRX
Relative Strength Index (RSI) 70.52 68.12
Support Level $6.90 $21.90
Resistance Level N/A $33.47
Average True Range (ATR) 1.41 1.75
MACD 0.40 0.07
Stochastic Oscillator 90.06 91.93

Price Performance

Historical Comparison
FCEL
LBRX

About FCEL FuelCell Energy Inc.

FuelCell Energy Inc is a clean energy technology company engaged in the development, design, production, and servicing of high temperature fuel cells for clean electric power generation. The Company provides proprietary molten carbonate fuel cell systems that generate electricity electrochemically with ultra low emissions and high efficiency, and operates as a solutions provider managing the design, manufacturing, installation, and maintenance of its systems under long term power purchase, service, and engineering procurement agreements. The Company serves utilities, data centers, and commercial and industrial customers, and operates in the United States, South Korea, Europe, and Canada, with maximum revenue generated from the United States.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.

Share on Social Networks: